All federal actions alleging internal bleeding from the use of Eliquis have been consolidated for pre-trial discovery. On February 7, 2017, the U.S. Judicial Panel on Multidistrict Litigation transferred 53 actions in 17 federal districts to the U.S. District Court for the Southern District of New York. The cases will be assigned to Judge Denise L. Cote who was presiding over the 16 cases that were already filed in the Southern District.
All of the actions in federal court share common allegations arising from plaintiffs suffering severe bleeding as a result of taking Eliquis. Since its approval in 2012, there has been a growing concern among physicians regarding the absence of guidance for dealing with uncontrollable bleeds from this drug. There have been numerous studies published after approval of Eliquis that confirm this problematic bleeding and critique the total lack of guidance on how to potentially stop a bleeding event once one occurs.
In its order transferring the cases, the Panel stated that “issues concerning the design, testing, manufacture, regulatory approval, labeling, and marketing of Eliquis are common to all actions.” The consolidation of the cases will also eliminate unnecessary duplicative discovery, eliminate inconsistent rulings, and conserve resources of the parties and court.
Harford, P.C., is currently accepting Eliquis induced internal bleeding cases in all 50 states. If you or someone you know have been injured from the use of Eliquis, you should contact us today for a free consultation.
Please contact us today at (212) 390-8983.
